Drug Database
Back to search

Poland· PL-100012974

Cardioxane

A dexrazoxane product containing dexrazoxanum, registered in Poland by Clinigen Healthcare B.V.. The same ATC class is registered in 15 of our 19 countries.

ATC V03AF02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedCardioxaneATCV03AF02REGISTER NO.PL-100012974PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dexrazoxanumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dexrazoxane is registered in 15 of 19 countries.

Countries holding a registration under ATC V03AF02 (dexrazoxane), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search dexrazoxane products by name

Dexrazoxane · ATC V03AF02

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of dexrazoxane costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Dexrazoxane · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

  • FI Finland$8.88
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Dexrazoxanum
Manufacturer
Clinigen Healthcare B.V.
Country
Poland (PL)
ATC code
V03AF02
ATC class
Dexrazoxane
Defined daily dose
1.5 g, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05060229220172

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

8 interactions on record for dexrazoxane.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dexrazoxane against other medicinesHow interaction checks work

Dexrazoxane · interactions on record

8 records

  • 2 severe
  • 6 moderate

Most severe, free to view

  • Talimogene laherparepvecL01XL02severe
  • Talimogen laherparepvecL01XX51severe
  • Lactobacillus acidophilusJ07AX04moderate
  • DoxorubicinL01DB01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dexrazoxane in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dexrazoxane products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Cyrdanax
  • Czechia · Cyrdanax
  • Germany · Cardioxane, Cyrdanax
  • Spain · Cardioxane
  • France · Cardioxane, Cyrdanax
  • United Kingdom (Northern Ireland) · Cardioxane
  • Hungary · Cyrdanax
  • Iceland · Savene
  • Italy · Cardioxane
  • Liechtenstein · Savene
  • Netherlands · Cardioxane
  • Norway · Savene
  • Romania · Cyrdanax
  • Slovakia · Cyrdanax

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d87b697d-e350-4202-add0-a6ca2e2f7870
GET /v1/drugs/d87b697d-e350-4202-add0-a6ca2e2f7870?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do infuzji",
  "source": "urpl",
  "strength": "500 mg",
  "packaging": "05060229220172 ¦ Rp ¦ 46890\n1 fiol. 500 mg",
  "substance": "Dexrazoxanum 500 mg",
  "common_name": "Dexrazoxanum",
  "pl_product_id": "100012974",
  "pozwolenie_nr": "01699",
  "auth_procedure": "MRP",
  "authorisation_validity": "2024-02-12"
}
API referenceMCP serverPlans

See everything about dexrazoxane.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console